XML 25 R34.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Product Revenue (Tables)
 12 Months Ended
Dec. 31, 2019
Revenue from Contract with Customer [Abstract]  
Schedule of Product Revenue
Our wholly owned product, TIBSOVO®, received approval from the FDA on July 20, 2018 for the treatment of adult patients with R/R AML with a susceptible IDH1 mutation. Upon FDA approval of TIBSOVO® in the U.S., we began generating product revenue from U.S. sales of TIBSOVO®.
(In thousands)201920182017
Product revenue, net$59,851  $13,841  $—  
Schedule of Product Revenue Allowance and Reserves
The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the year ended December 31, 2019:
(In thousands)Contractual
Adjustments		Government
Rebates		ReturnsTotal
Balance at December 31, 2018592  325  334  1,251  
Current provisions relating to sales in the current year7,899  2,387  1,464  11,750  
Adjustments relating to prior years8  (41) —  (33) 
Payments/returns relating to sales in the current year(7,027) (1,286) —  (8,313) 
Payments/returns relating to sales in the prior years(598) (261) —  (859) 
Balance at December 31, 2019874  1,124  1,798  3,796  
The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the year ended December 31, 2018:
(In thousands)Contractual
Adjustments		Government
Rebates		ReturnsTotal
Balance at December 31, 2017—  —  —  —  
Current provisions relating to sales in the current year1,777  422  334  2,533  
Adjustments relating to prior years—  —  —  —  
Payments/returns relating to sales in the current year(1,185) (97) —  (1,282) 
Payments/returns relating to sales in the prior years—  —  —  —  
Balance at December 31, 2018592  325  334  1,251  
Schedule of Revenue Related Reserves
Total revenue-related reserves for the years ended December 31, 2019 and 2018 above, included in our consolidated balance sheets, are summarized as follows:
(In thousands)December 31,
2019		December 31,
2018
Reduction of accounts receivable$540  $326  
Component of accrued expenses3,256  925  
Total revenue-related reserves$3,796  $1,251  
Schedule of Changes in Contract Assets and Liabilities
The following table presents changes in our contract assets and liabilities during the year ended December 31, 2019:
(In thousands)December 31,
2018		AdditionsDeductionsDecember 31,
2019
Contract assets
Accounts receivable, net (1)
$5,076  $71,542  $(67,666) $8,952  
(1) Additions to accounts receivable, net relate to amounts billed to Customers for product sales and deductions primarily relate to collection of receivables during the reporting period.
The following table presents changes in our contract assets and liabilities during the year ended December 31, 2018:
(In thousands)December 31,
2017		AdditionsDeductionsDecember 31,
2018
Contract assets
Accounts receivable, net (1)
$—  $16,374  $(11,298) $5,076  
(1) Additions to accounts receivable, net relate to amounts billed to Customers for product sales and deductions primarily relate to collection of receivables during the reporting period.